<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01811849</url>
  </required_header>
  <id_info>
    <org_study_id>4-102</org_study_id>
    <nct_id>NCT01811849</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Injection Site Toleration of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects With Type 1 Diabetes</brief_title>
  <official_title>A Double-blind Study of the Pharmacokinetic Properties of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Safety and Injection Site Toleration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biodel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biodel</source>
  <brief_summary>
    <textblock>
      A Double-blind Study of the Pharmacokinetic Properties of BIOD-238 and BIOD-250 Compared to
      Humalog® in Subjects with Type 1 Diabetes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the speed of absorption of BIOD-238 and BIOD-250
      compared to Humalog®. Secondary objectives are to assess other pharmacokinetic
      characteristics of BIOD-238 and BIOD-250 compared to Humalog®, and to evaluate the safety and
      tolerability of BIOD-238 and BIOD-250 compared to Humalog®.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to 1/2 maximal insulin concentration</measure>
    <time_frame>480 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximal insulin concentration</measure>
    <time_frame>480 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 1/2 maximal insulin concentration after peak</measure>
    <time_frame>480 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analog scale</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-30 and AUC 0-60</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>BIOD-238</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIOD-250</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin LISPRO</intervention_name>
    <arm_group_label>BIOD-238</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin LISPRO</intervention_name>
    <arm_group_label>BIOD-250</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin LISPRO</intervention_name>
    <arm_group_label>Humalog</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: ≥18 to ≤70 years

          -  Body Mass Index: ≥18 and ≤35 kg/m2

          -  Diagnosed with Type 1 Diabetes Mellitus for at least 1 year

        Exclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Serum C-peptide &gt;1.0 ng/mL

          -  HbA1c &gt;10.0%

          -  History of hypersensitivity to any of the components in the study medication

          -  Treatment with any other investigational drug in the last 30 days before dosing.

          -  Current drug or alcohol abuse, or a history of drug or alcohol abuse which in the
             opinion of the Investigator will impair subject safety, protocol compliance, or
             interpretation of study results. Caffeine, nicotine or alcohol addiction which might
             be expected to result in withdrawal symptoms during the course of a study dosing day
             would fall into this category.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2013</study_first_submitted>
  <study_first_submitted_qc>March 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2013</study_first_posted>
  <last_update_submitted>March 14, 2013</last_update_submitted>
  <last_update_submitted_qc>March 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

